Article
Mutations Defining Patient Cohorts With Elevated PD-L1 Expression in Gastric Cancer
8 Jan 2019
Abstract excerpt
The immunotherapy agent pembrolizumab has been approved for gastric cancer (GC) patients with recurrent or advanced disease who are PD-L1 positive. Mutations in the primary lesion may drive the expression of immune targets thereby priming the tumor to therapeutic sensitivity. In this study, we aimed to uncover mutations associated with elevated PD-L1 expression in GC patients. Data from 410 GC patients were...
Topics
Join the communities discussing this publication.